Cost-effectiveness of continuous combined hormone replacement therapy in long-term use: Economic evaluation based on a 9-year study in Finland

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 57-64

  Ylikangas, Stiina ^a   Bäckström, Torbjörn ^b   Heikkinen, Jorma ^c  

^a Orion Pharma   (Sweden)

^b Umea Neurosteroid Research Center   (Sweden)

^c OULU DEACONESS INSTITUTE   (Finland)

Author keywords

Cancer; CHD; Cost effectiveness; Fracture; Low dose continuous combined hormone replacement therapy; Quality adjusted life year, QALY; Stroke

Indexed keywords

ESTRADIOL VALERATE; INDIVINA; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MIXTURE; ECONOMIC ASPECT; FEMALE; FINLAND; HORMONE SUBSTITUTION; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REGISTER;

AGED; COST-BENEFIT ANALYSIS; FEMALE; FINLAND; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POSTMENOPAUSE; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS;

EID: 33846695912     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X159542     Document Type: Article

References (53)

1. Maclennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978
2. North American Menopause Society. Recommendations for estrogen and progestogen use in peri- and postmenopausal women: October 2004 position statement of the North American Menopause Society. Menopause 2004;11:589-600
3. Naftolin F, Schneider HPG, Sturdee DW, et al.; for The Writing Group of the IMS Executive Committee. Guidelines for hormone treatment of women in the menopausal transition and beyond: position statement by the Executive Committee of the International Menopause Society. Climacteric 2004;7:333-7
4. Skouby SO. EMAS position paper 2004. Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy. Maturitas 2004;48:19-25
5. Hickey M, Davis SR, Sturdee SW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-21
6. Hillard TC. No-bleed preparations. J Br Menopause Soc 2002;8(Suppl):S11
7. Heikkinen J, Vaheri R, Ahomäki S, et al. Optimizing continuous-combined hormone replacement therapy for postmenopausal women. A comparison of six different regimens. Am J Obstet Gynecol 2000;182:560-7
8. Heikkinen J, Vaheri R, Kainulainen P, et al. Long-term continuous combined hormone replacement therapy in the prevention of postmenopausal osteoporosis: a comparison of high and low dose estrogen-progestin regimens. Osteoporosis Int 2000;11:929-37
9. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of continuous-combined hormone therapy in postmenopausal women: results from a seven-year randomized comparison of low and standard doses. J Br Menopause Soc 2004;7:95-102
10. Sintonen H, Johansson S, Ohinmaa A, et al. Measuring health-related quality of life in women on hormone replacement therapy. Expert Rev Pharmacoeconomics Outcomes Res 2003;3:351-61
11. Fleurance RL. Issues in the economic evaluation of treatments for menopausal symptoms. J Br Menopause Soc 2001;7:120-4
12. Mullins CD, Ohsfeldt RL. Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 2003;9:150-8
13. Swift JA, Conway P, Purdie DW. A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus. Curr Med Res Opin 2005;21:2051-61
14. Botteman MF, Shah NP, Lian J, et al. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms. Menopause 2004;11:343-55
15. Coyle D, Cranney A, Tugwell P. Economic evaluation of norethisterone acetate/ethinylestradiol (FemHRT) for women with menopausal symptoms. Pharmacoeconomics 2003;21:661-9
16. Ylikangas S, Sintonen H, Heikkinen J. Decade-long use of continuous combined hormone replacement therapy is associated with better health-related quality of life in postmenopausal women, as measured by the generic 15D instrument. J Br Menopause Soc 2005;11:145-51
17. Kettula M. Functionality of the chain of care for patients with myocardial infarction and the distribution of costs per patient in southern Ostrobothnia [academic dissertation]. Acta Universitas Tamperensis 2001;823
18. Zethraeus N, Molin T, Henriksson P, et al. Costs of coronary heart disease and stroke: the case of Sweden. J Intern Med 1999;246:151-9
19. Kanis JA, Borgstrom F, Johnell O, et al. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporosis Int 2005;16:15-25
20. Porsdal V, Boysen G. Costs of health care and social services during the first year after ischemic stroke. Int J Technol Assess Health Care 1999;15:573-84
21. Van Exel J, Koopmanschap MA, Van Wijngaarden JD, et al. Costs of stroke and stroke services: determinants of patient costs and a comparison of costs of regular care and care organised in stroke services. Cost Eff Resour Alloc 2003;1:2
22. Dewey HM, Thrift AG, Mihalopoulos C, et al. Cost of stroke in Australia from a societal perspective: results from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2001;32:2409-16
23. Claesson L, Gosman-Hedström G, Johannesson M, et al. Resource utilization and costs of stroke unit care integrated in a care continuum: a 1-year controlled, prospective, randomized study in elderly patients [The Göteborg 70+ Stroke Study]. Stroke 2000;31:2569-77
24. Kaste M, Fogelholm R, Rissanen A. Economic burden of stroke and evaluation of new therapies. Public Health 1998;112:103-12
25. Taplin SH, Barlow W, Urban N, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care. J Natl Cancer Inst 1995;87:417-26
26. Bouvier V, Reaud JM, Gignoux M, et al. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados Departement, France. Eur J Health Econ 2003;4:102-6
27. Borgstrom F, Johnell O, Kanis JA, et al. Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 2004;22:1153-65
28. Bradley CJ, Given C, Baser O, et al. Influence of surgical and treatment choices on the cost of breast cancer care. Eur J Health Econ 2003;4:96-101
29. Lindsay R, Burge RT, Strauss DM. One year outcomes and costs following a vertebral fracture. Osteoporosis Int 2005;16:78-85
30. Nurmi I, Narinen A, Luthje P, et al. Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg 2003;123:551-4
31. Jönsson B. Targeting high-risk populations. Osteoporosis Int 1998;(Suppl 1):513-6
32. Drummond M, O'Brien B, Stoddart G, et al. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford: Oxford Medical Publications; 1997. p. 16
33. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann Med 2001;33:328-36
34. Hawthorne G, Richardson J, Day NA. A comparison of the assessment of quality of life (AQoL) with four other generic utility instruments. Ann Med 2001;33:358-70
35. Topo P, Klaukka T, Hemminki E, et al. Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women. J Epidemiol Community Health 1991;45:277-80
36. Faber A, Bouvy ML, Loskamp L, et al. Dramatic change in prescribing of hormone replacement therapy in the Netherlands after publication of the Million Women Study: a follow-up study. Br J Clin Pharmacol 2005;60:641-7
37. Zethraeus N, Borgström F, Jönsson B, et al. Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: Results based on the Women's Health Initiative randomized controlled trial. Int J Technology Assessment Health Care 2005;21:433-41
38. Minelli C, Abrams KR, Sutton AJ, et al. Benefits and harms associated with hormone replacement therapy: clinical decision analysis. Br Med J 2004;328:371-7
39. Daly E, Gray A, Barlow D, et al. Measuring the impact on menopausal symptoms on quality of life. Br Med J 1993;307:841-4
40. Ledesert B, Ringa V, Breart G. Menopause and perceived health status among the women of the French GAZEL cohort. Maturitas 1994;20:113-20
41. Burton WN, Pransky G, Conti DJ, et al. The association of medical conditions and presenteeism. J Occup Environ Med 2004;46:S38-S45
42. Bobula JD. Vasomotor symptoms and quality of life (QoL) in postmenopausal women. Value Health 2003;6:707-12
43. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
44. Zethraeus N, Henriksson P, Strand RT. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol 1997;104:1191-5
45. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001;32:964-72
46. Honkanen RJ, Honkanen K, Kroger H, et al. Risk factors for perimenopausal distal forearm fractures. Osteoporosis Int 2000;11:265-70
47. Cranney A, Guyatt G, Griffith L, et al. Osteoporosis Methodology Group, and the Osteoporosis Research Advisory Group. IX: summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrin Rev 2002;23:570-8
48. Vihtamaki T, Savilahti R, Tuimala R. Why do postmenopausal women discontinue hormone replacement therapy? Maturitas 1999;33:99-105
49. Soljak MA. Risk factor thresholds. Br Med J 2002;325:1113 [letter]
50. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004;13:437-52
51. Pitkin J, Rees MC, Gray S, et al. Managing the menopause; BMS Council Consensus Statement. J Br Menopause Soc 2004;10:33-6
52. Shmuely Y, Berlin JA, Knauss J, et al. Compliance with oral HRT in postmenopausal women in clinical trials/meta analysis. Maturitas 2003;46:33-44
53. Leung KY, Ling M, Tang GWK. Continuation rate of hormone replacement therapy in Hong Kong public health sector. Maturitas 2004;49:338-44